The Molecular Tumor Board consists of physician-scientists, clinicians and researchers in the field of tumor genetics.

Created in 2017, the board recommends advanced molecular testing for patients who meet certain criteria to help diagnose and manage central nervous system tumors.  Various tests are performed to detect novel mutations and pathways involved in tumor growth, including rapid whole genome sequencing.

Team

Robert Wechsler Reya, Ph.D., Director, Joseph Clayes III Research Center for Neuro-Oncology and Genomic Medicine; Director, Tumor Initiation and Maintenance Program Sanford Burnham Prebys (SBP) Medical Discovery Institute

Jennifer Elster, M.D., Medical Director, Pediatric Proton Therapy Program

Michael Levy, M.D., Ph.D., Chief, Division of Neurosurgery

Denise Malicki M.D., Ph.D., Neuropathologist, Division of Pathology

Jill Mesirov, Ph.D., UC San Diego School of Medicine

Hannah Carter Ph.D., UC San Diego School of Medicine

Pablo Tamayo Ph.D., UC San Diego School of Medicine

Lukas Chavez Ph.D., UC San Diego School of Medicine